{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:40:40Z","timestamp":1792784440246,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grunenthal","id":[{"id":"https:\/\/ror.org\/05grp4x11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s12325-017-0654-0","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T06:25:22Z","timestamp":1513837522000},"page":"12-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic"],"prefix":"10.1007","volume":"35","author":[{"given":"Ariane","family":"Stollenwerk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Sohns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Heisig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Elling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"von Zabern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"key":"654_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ejpain.2010.06.017","volume":"14","author":"HG Kress","year":"2010","unstructured":"Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14:781\u20133.","journal-title":"Eur J Pain"},{"key":"654_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40263-014-0151-9","volume":"28","author":"TM Tzschentke","year":"2014","unstructured":"Tzschentke TM, Christoph T, K\u00f6gel BY. The mu-opioid receptor agonist\/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs. 2014;28:319\u201329.","journal-title":"CNS Drugs"},{"key":"654_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1124\/jpet.110.175042","volume":"337","author":"W Schr\u00f6der","year":"2011","unstructured":"Schr\u00f6der W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther. 2011;337:312\u201320.","journal-title":"J Pharmacol Exp Ther"},{"key":"654_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1358\/mf.2010.32.1.1434165","volume":"32","author":"R Terlinden","year":"2010","unstructured":"Terlinden R, Kogel BY, Englberger W, Tzschentke TM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol. 2010;32:31\u20138.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"654_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF03190478","volume":"32","author":"R Terlinden","year":"2007","unstructured":"Terlinden R, Ossig J, Fliegert F, Lange C, G\u00f6hler K. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2007;32:163\u20139.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"654_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/187231208783478434","volume":"2","author":"C Kneip","year":"2008","unstructured":"Kneip C, Terlinden R, Beier H, Chen G. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008;2:67\u201375.","journal-title":"Drug Metab Lett"},{"key":"654_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1592\/phco.30.1.25","volume":"30","author":"JW Smit","year":"2010","unstructured":"Smit JW, Oh C, Rengelshausen J, et al. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, cross-over, drug-drug interaction studies. Pharmacotherapy. 2010;30:25\u201334.","journal-title":"Pharmacotherapy"},{"key":"654_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw154","author":"JP Xiao","year":"2016","unstructured":"Xiao JP, Li AL, Feng BM, Ye Y, Wang GJ. Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain: a systematic review and meta-analysis. Pain Med. 2016. https:\/\/doi.org\/10.1093\/pm\/pnw154 .","journal-title":"Pain Med"},{"key":"654_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12515","author":"R Baron","year":"2016","unstructured":"Baron R, Eberhart L, Kern KU, et al. Tapentadol prolonged release for chronic pain\u2014a review of clinical trials and five years of routine clinical practice data. Pain Pract. 2016. https:\/\/doi.org\/10.1111\/papr.12515 .","journal-title":"Pain Pract"},{"key":"654_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1185\/03007990902728183","volume":"25","author":"SE Daniels","year":"2009","unstructured":"Daniels SE, Upmalis D, Okamoto A, Lange C, Haeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009;25:765\u201376.","journal-title":"Curr Med Res Opin"},{"key":"654_CR11","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1185\/03007990902952825","volume":"25","author":"S Daniels","year":"2009","unstructured":"Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009;25:1551\u201361.","journal-title":"Curr Med Res Opin"},{"key":"654_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5055\/jom.2013.0170","volume":"9","author":"GJ Vorsanger","year":"2013","unstructured":"Vorsanger GJ, Klopfer AM, Xiang J, Benson CJ, Moskovitz BL, Rosenthal NR. Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study. J Opioid Manag. 2013;9:281\u201396.","journal-title":"J Opioid Manag"},{"key":"654_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clinthera.2009.02.009","volume":"31","author":"C Hartrick","year":"2009","unstructured":"Hartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009;31:260\u201371.","journal-title":"Clin Ther"},{"key":"654_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1185\/03007990902816970","volume":"25","author":"M Hale","year":"2009","unstructured":"Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90\u00a0days: a randomized, double-blind study. Curr Med Res Opin. 2009;25:1095\u2013104.","journal-title":"Curr Med Res Opin"},{"key":"654_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"M Afilalo","year":"2010","unstructured":"Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pin related to osteoarthritis of the knee. Clin Drug Investig. 2010;30:489\u2013505.","journal-title":"Clin Drug Investig"},{"key":"654_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1533-2500.2010.00397.x","volume":"10","author":"JE Wild","year":"2010","unstructured":"Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10:416\u201327.","journal-title":"Pain Pract"},{"key":"654_CR17","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","volume":"11","author":"R Buynak","year":"2010","unstructured":"Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother. 2010;11:1787\u2013804.","journal-title":"Expert Opin Pharmacother"},{"key":"654_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/papr.12200","volume":"15","author":"R Baron","year":"2015","unstructured":"Baron R, Martin-Mola E, M\u00fcller M, Dubois C, Falke D, Steigerwald I. Effectiveness and safety of tapentadol prolonged release (PR) versus a combination of tapentadol PR and pregabalin for the management of severe, chronic low back pain with a neuropathic component: a randomized, double-blind, phase 3b study. Pain Pract. 2015;15:455\u201370.","journal-title":"Pain Pract"},{"key":"654_CR19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/papr.12308","volume":"16","author":"R Baron","year":"2016","unstructured":"Baron R, Likar R, Martin-Mola E, et al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone\/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b\/4 study. Pain Pract. 2016;16:580\u201399.","journal-title":"Pain Pract"},{"key":"654_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1185\/03007995.2010.537589","volume":"27","author":"S Schwartz","year":"2011","unstructured":"Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27:151\u201362.","journal-title":"Curr Med Res Opin"},{"key":"654_CR21","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.2337\/dc13-2291","volume":"37","author":"AI Vinik","year":"2014","unstructured":"Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic, painful diabetic peripheral neuropathy. Diabetes Care. 2014;37:2302\u20139.","journal-title":"Diabetes Care"},{"key":"654_CR22","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1185\/03007995.2013.831816","volume":"29","author":"K Imanaka","year":"2013","unstructured":"Imanaka K, Tominaga Y, Etropolski M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin. 2013;29:1399\u2013409.","journal-title":"Curr Med Res Opin"},{"key":"654_CR23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.36076\/ppj.2014\/17\/329","volume":"17","author":"HG Kress","year":"2014","unstructured":"Kress HG, Koch ED, Kosturski H, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014;17:329\u201343.","journal-title":"Pain Physician"},{"key":"654_CR24","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1016\/j.clinthera.2015.08.014","volume":"37","author":"R Buynak","year":"2015","unstructured":"Buynak R, Rappaport SA, Rod K, et al. Long-term safety and efficacy of tapentadol extended release following up to 2\u00a0years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin Ther. 2015;37:2420\u201338.","journal-title":"Clin Ther"},{"key":"654_CR25","unstructured":"Electronic Medicines Compendium. Palexia film coated tablets. https:\/\/www.medicines.org.uk\/emc\/medicine\/28375 . Accessed Feb 15, 2017."},{"key":"654_CR26","unstructured":"Electronic Medicines Compendium. Palexia SR prolonged release tablets. https:\/\/www.medicines.org.uk\/emc\/medicine\/28373 . Accessed Sept 19, 2016."},{"key":"654_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1358\/dof.2006.031.12.1047744","volume":"31","author":"TM Tzschentke","year":"2006","unstructured":"Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol hydrochloride. Analgesic mu-opioid receptor agonist noradrenaline reuptake inhibitor. Drugs Future. 2006;31:1053\u201361.","journal-title":"Drugs Future"},{"key":"654_CR28","doi-asserted-by":"publisher","first-page":"h2102","DOI":"10.1136\/bmj.h2102","volume":"350","author":"RJ Desai","year":"2015","unstructured":"Desai RJ, Huybrechts KF, Hernandez-Diaz S, et al. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. BMJ. 2015;350:h2102.","journal-title":"BMJ"},{"key":"654_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1055\/s-0035-1556740","volume":"4","author":"MM Yadzy","year":"2015","unstructured":"Yadzy MM, Desai RJ, Brogly SB. Prescription opioids in pregnancy and birth outcomes: a review of the literature. J Pediatr Genet. 2015;4:56\u201370.","journal-title":"J Pediatr Genet"},{"key":"654_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/bcpt.12497","volume":"118","author":"D Lassen","year":"2016","unstructured":"Lassen D, Ennis ZN, Damkier P. First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: a systematic review. Basic Clin Pharmacol Toxicol. 2016;118:32\u20136.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"654_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hup.2473","volume":"30","author":"C Bellantuono","year":"2015","unstructured":"Bellantuono C, Vargas M, Mandarelli G, Nardi B, Martini MG. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol. 2015;30:143\u201351.","journal-title":"Hum Psychopharmacol"},{"key":"654_CR32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/bja\/aei210","volume":"95","author":"PK Gillman","year":"2005","unstructured":"Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95:434\u201341.","journal-title":"Br J Anaesth"},{"key":"654_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1517\/14740338.7.5.587","volume":"7","author":"C Sun-Edelstein","year":"2008","unstructured":"Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008;7:587\u201396.","journal-title":"Expert Opin Drug Saf"},{"key":"654_CR34","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","volume":"96","author":"EJC Dunkley","year":"2003","unstructured":"Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med. 2003;96:635\u201342.","journal-title":"Q J Med"},{"key":"654_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1124\/jpet.107.126052","volume":"323","author":"TM Tzschentke","year":"2007","unstructured":"Tzschentke TM, Christoph T, K\u00f6gel B, et al. (\u2212)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel \u00b5-opioid receptor agonist\/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Expert Ther. 2007;323:265\u201376.","journal-title":"J Pharmacol Expert Ther"},{"key":"654_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neulet.2010.12.049","volume":"490","author":"P Bloms-Funke","year":"2011","unstructured":"Bloms-Funke P, Dremencov E, Cremers TI, Tzschentke TM. Tramadol increases extracellular levels of serotonin and noradrenaline as measured by in vivo microdialysis in the ventral hippocampus of freely-moving rats. Neurosci Lett. 2011;490:191\u20135.","journal-title":"Neurosci Lett"},{"key":"654_CR37","doi-asserted-by":"crossref","unstructured":"Schr\u00f6der W, De Vry J, Tzschentke TM, Jahnel U, Christoph T. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain. 2010:814\u201321.","DOI":"10.1016\/j.ejpain.2010.05.005"},{"key":"654_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1310\/hpj5104-320","volume":"51","author":"H Walczyk","year":"2016","unstructured":"Walczyk H, Liu CH, Alafris A, Cohen H. Probable tapentadol-associated serotonin syndrome after overdose. Hosp Pharm. 2016;51:320\u20137.","journal-title":"Hosp Pharm"},{"key":"654_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bja\/aen094","volume":"100","author":"KTS Pattinson","year":"2008","unstructured":"Pattinson KTS. Opioids and the control of respiration. Br J Anaesth. 2008;100:747\u201358.","journal-title":"Br J Anaesth"},{"key":"654_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.resp.2008.02.004","volume":"164","author":"PM Lalley","year":"2008","unstructured":"Lalley PM. Opioidergic and dopaminergic modulation of respiration. Respir Physiol Neurobiol. 2008;164:160\u20137.","journal-title":"Respir Physiol Neurobiol"},{"key":"654_CR41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/jat\/bks041","volume":"36","author":"SJ Larson","year":"2012","unstructured":"Larson SJ, Pestaner J, Prashar SK, Bayard C, Zarwell LW, Pierre-Louis M. Postmortem distribution of tapentadol and n-desmethyltapentadol. J Anal Toxicol. 2012;36:440\u20133.","journal-title":"J Anal Toxicol"},{"key":"654_CR42","first-page":"547","volume-title":"Goodman and Gilman\u2019s. The pharmacological basis of therapeutics","author":"HB Gutstein","year":"2006","unstructured":"Gutstein HB, Akil H. Opioid analgesics. In: Brunton L, editor. Goodman and Gilman\u2019s. The pharmacological basis of therapeutics. 11th ed. Pennsylvania: McGraw-Hill; 2006. p. 547\u201390.","edition":"11"},{"key":"654_CR43","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1124\/jpet.108.137273","volume":"325","author":"RB Raffa","year":"2008","unstructured":"Raffa RB, Stone DJ. Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice. J Pharmacol Exp Ther. 2008;325:500\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"654_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1592\/phco.20.7.629.35174","volume":"20","author":"C Gasse","year":"2000","unstructured":"Gasse C, Derby L, Vasilakis-Scaramozza C, Jick H. Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy. 2000;20:629\u201334.","journal-title":"Pharmacotherapy"},{"key":"654_CR45","unstructured":"Food and Drug Administration. Nucynta summary basis for approval. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/022304s000_PharmR_P5.pdf . Accessed June 15, 2017."},{"key":"654_CR46","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s12325-014-0128-6","volume":"31","author":"M Etropolski","year":"2014","unstructured":"Etropolski M, Kuperwasser B, Fl\u00fcgel M, et al. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. Adv Ther. 2014;31:604\u201320.","journal-title":"Adv Ther"},{"key":"654_CR47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1155\/2011\/323985","volume":"16","author":"G Vorsanger","year":"2011","unstructured":"Vorsanger G, Xiang J, Biondi D, et al. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients. Pain Res Manag. 2011;16:245\u201351.","journal-title":"Pain Res Manag"},{"key":"654_CR48","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/papr.12361","volume":"16","author":"R Baron","year":"2016","unstructured":"Baron R, Jansen JP, Binder A, et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone\/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b\/4 trial. Pain Pract. 2016;16:600\u201319.","journal-title":"Pain Pract"},{"key":"654_CR49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.5055\/jom.2015.0289","volume":"11","author":"DM Biondi","year":"2015","unstructured":"Biondi DM, Xiang J, H\u00e4ufel T, Etropolski M, Moskovitz B. Tolerability and efficacy of tapentadol extended release in elderly patients\u00a0\u2265\u00a075\u00a0years of age with chronic osteoarthritis knee or low back pain. J Opioid Manag. 2015;11:393\u2013403.","journal-title":"J Opioid Manag"},{"key":"654_CR50","unstructured":"Janssen Pharmaceuticals. NUCYNTA ER-tapentadol hydrochloride tablet, film coated, extended release. https:\/\/www.nucynta.com\/sites\/default\/files\/pdf\/nucyntaer-pi_0.pdf . Accessed Mar 6, 2017."},{"key":"654_CR51","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1310\/hpj5204-246","volume":"52","author":"ME Mullins","year":"2017","unstructured":"Mullins ME, Dribben WH. Comment on tapentadol and serotonin syndrome. Hosp Pharm. 2017;52:246\u20137.","journal-title":"Hosp Pharm"},{"key":"654_CR52","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1310\/hpj5204-248","volume":"52","author":"M Russo","year":"2017","unstructured":"Russo M, Santarelli D, Isbister G. Comment on \u201cprobable tapentadol-associated serotonon syndrome after overdose\u201d. Hosp Pharm. 2017;52:248.","journal-title":"Hosp Pharm"},{"key":"654_CR53","first-page":"265","volume":"25","author":"V Brett","year":"2012","unstructured":"Brett V, Sikes C, Xiang J, Oh C, Biondi D. Post hoc analysis of pooled safety data from eleven phase 3 clinical trials to identify potential pharmacodynamic drug interactions between tapentadol and SSRIs\/SNRIs. J Pharm Pract. 2012;25:265.","journal-title":"J Pharm Pract"},{"key":"654_CR54","unstructured":"Schmidt P. Safety information on serotonin syndrome for tapentadol IR and tapentadol ER administration (Abstract poster 212). http:\/\/www.painmed.org\/2016posters\/abstract-212\/ . Accessed Sept 26, 2016."},{"key":"654_CR55","doi-asserted-by":"crossref","unstructured":"van der Schrier R, Jonkman K, van Velzen M, et al. An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers. Br J Anaesth 2017;119(6):1169.","DOI":"10.1093\/bja\/aex295"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0654-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0654-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0654-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T19:51:04Z","timestamp":1660161064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0654-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,21]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["654"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0654-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,21]]},"assertion":[{"value":"13 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}